Table 3.

Scaffold 2

#	-R1	-R2	-R3	-R4	IC50 (95% CI), μM	Hill slope (95% CI)
2aa	-H	-CH2CH3	4-Br		67 (34–135)	−0.7 (−1.0, −0,4)
2ab	-H	-CH2CH3			weak inhibitor a
2ac	-(CH2)3COOH	-CH2CBr3	-H	-CH3	31 (26 – 38)	−1.6 (−2.0, −1.3)
2ad	-(CH2)3COOH	-CH2CBr3	4-Br	-CH3	inhibitorb
2ae	-(CH2)3COOH	-CH2CBr3	3-NO2	-CH3	25 (16–37)	−1.4 (−2.1, −0.7)
2af	-(CH2)3COOH	-CH2CH3	3-NO2	-CH3	inactive
2ag	-(CH2)3COOH		-H	-CH3	inactive
2ah	-(CH2)3COOH		4-Br	-CH3	51 (31–83)	n.dc
2ai	-(CH2)3COOH		4-NO2	-CH3	Weak inhibitor b
2aj	-(CH2)3COOH			-CH3	79 (68 – 92)	−2.0 (−2.9, −1.1)
2ak	-(CH2)3COOH			-CH3	weak inhibitor a
2al	-(CH2)3COOH		2-Cl, 3-Cl	-CH3	15 (13 – 17)	−2.2 (−3.2, −1.1)
2am	-(CH2)3COOH		2-Cl, 4-Cl	-CH3	140 (86 – 227)	−1.3 (−2.0, − 0.60)
2an	-(CH2)5COOH	-CH2CH3	4-NO2	-CH3	96 (40–231)	−1.8 (−4.7 ; 1.2)
2ao	-(CH2)5COOH	-CH2CH3	3-NO2	-CH3	Weak inhibitora
2ap	-(CH2)5COOH	-CH2CH3	4-OCH3	-CH3	190 (102– 352)	−1.7 (−3.0, −0.4)
2aq	-(CH2)5COOH	-CH2CH3	4-Br	-CH3	74 (38 – 143)	−0.9 (−1.5, −0.4)
2ar	-(CH2)5COOH	-C(CH3)3	4-Br	-CH3	weak inhibitora
2as	-(CH2)5COOH	-CH3		-CH3	inhibitorb
2at	-(CH2)5COOH		-H	-CH3	52 (42 – 63)	−1.6 (−2.0, −1.2)
2au	-(CH2)5COOH		2-Cl	-CH3	25 (14 – 44)	−1.5 (−2.6, −0.4)
2av	-(CH2)5COOH		3-NO2	-CH3	25 (17 – 36)	−1.4 (−2.0, −0.8)
2aw	-(CH2)5COOH		3-C(CH3)3	-CH3	11 (7–17)	−2.2 (−4,0, −0.4)
2ax	-(CH2)5COOH		4-Cl	-CH3	14 (11 – 18)	−1.3 (−1.7, −0.9)
2ay	-(CH2)5COOH		4-Br	-CH3	45 (28 – 73)	−3.2 (−5.7, −0.7)
2az	-(CH2)5COOH		4-NO2	-CH3	26 (17 – 42)	−1.5 (−2.4, −0.7)
2ba	-(CH2)5COOH		4-CF3	-CH3	inhibitorb
2bb	-(CH2)5COOH		2-Cl, 3-Cl	-CH3	27 (13 – 56)	−0.9 (−1.3, −0.4)
2bc	-(CH2)5COOH		2-Cl, 4-Cl	-CH3	55 (38–79)	−1.6 (−2.5, −0.8)

^amodulatory effect estimated from three concentrations only;

^b4-parameter logistic model curve could not be fitted.

^cHill coefficient could not be calculated with significant accuracy (within 3 units).